Showing results (31-40 of 280) with videos related to
Sort By:
Pageof 28
Expert Review of Hematology|June 21, 2013
Higher-risk myelodysplastic syndromes with del(5q): is sequential azacitidine-lenalidomide combination the way to go?Amer M Zeidan, Steven D Gore, Rami S KomrokjiExpert Opinion on Investigational Drugs|January 26, 2016
Lost in translation? Ten years of development of histone deacetylase inhibitors in acute myeloid leukemia and myelodysplastic syndromesMaximilian Stahl, Steven D Gore, Norbert Vey, et al.Cancer Cell|July 9, 2021
Immune responses to COVID-19 vaccines in patients with cancer: Promising results and a note of cautionElizabeth A Griffiths, Brahm H SegalBlood Advances|November 15, 2018
When to obtain genomic data in acute myeloid leukemia (AML) and which mutations matterGregory W Roloff, Elizabeth A GriffithsHematology. American Society of Hematology. Education Program|December 4, 2018
When to obtain genomic data in acute myeloid leukemia (AML) and which mutations matterGregory W Roloff, Elizabeth A GriffithsBlood Reviews|February 8, 2020
BITES and CARS and checkpoints, oh my! Updates regarding immunotherapy for myeloid malignancies from the 2018 annual ASH meetingAmanda C Przespolewski, Elizabeth A GriffithsLeukemia & Lymphoma|September 23, 2016
Hypomethylating agent combination strategies in myelodysplastic syndromes: hopes and shortcomingsBrian Ball, Amer Zeidan, Steven D Gore, et al.Expert Opinion on Pharmacotherapy|July 5, 2017
Hypomethylating agents (HMA) treatment for myelodysplastic syndromes: alternatives in the frontline and relapse settingsNatalie Uy, Abhay Singh, Steven D Gore, et al.The Oncologist|July 22, 2015
Molecular Testing in Myelodysplastic Syndromes for the Practicing Oncologist: Will the Progress Fulfill the Promise?Aziz Nazha, Mikkael A Sekeres, Steven D Gore, et al.Molecular Cancer Therapeutics|November 9, 2005
Clinical translation of epigenetics in cancer: eN-CORe--a report on the second workshopArthur Zelent, Kevin Petrie, Reuben Lotan, et al.Pageof 28